

1 **Performance of RT-PCR on saliva specimens**  
2 **compared to nasopharyngeal swabs for the**  
3 **detection of SARS-CoV-2 in children: A prospective**  
4 **comparative clinical trial**

5 Yves Fougère<sup>1</sup>, Jean Marc Schwob<sup>2</sup>, Alix Miauton<sup>2</sup>, Francesca Hoegger<sup>3</sup>, Onya  
6 Opota<sup>4</sup>, Katia Jaton<sup>4</sup>, Rene Brouillet<sup>4</sup>, Gilbert Greub<sup>4,5</sup>, Blaise Genton<sup>2,5</sup>, Mario  
7 Gehri<sup>3</sup>, Ilaria Taddeo<sup>6</sup>, Valérie D'Acremont<sup>2,5</sup>, Sandra A. Asner<sup>1,5,7</sup>

8 1 Pediatric Infectious Diseases and Vaccinology Unit, Department Women-Mother-  
9 Child, Lausanne University Hospital, Switzerland

10 2. Tropical and Travel Medicine Unit, Center for Primary Care and Public Health  
11 (Unisanté), Switzerland

12 3 Service of Pediatrics, Department Women-Mother-Child, Lausanne University  
13 Hospital, Switzerland

14 4. Institute of Microbiology, Lausanne University Hospital, Switzerland

15 5. University of Lausanne

16 6 Pediatric Emergency Center, Vidy-Med, Lausanne, Switzerland

17 7. Infectious Diseases Service, Department of Medicine, Lausanne University  
18 Hospital, University of Lausanne, Switzerland

19 **Keywords: SARS-COV-2, saliva, Viral loads, children, sensitivity**

20 **Running title: Saliva PCR for SARS-CoV-2 detection in children**

21 **Corresponding author:**

22 Sandra A Asner, MD, MSc

23 Pediatric Infectious Diseases and Vaccinology Unit

24 Department Mother-Woman-Child; Lausanne University Hospital

25 Rue du Bugnon 46; CH-1011 Lausanne, Switzerland

26 Phone: +41 21 314 10 79, email: [Sandra.Asner@chuv.ch](mailto:Sandra.Asner@chuv.ch)

27 ORCID iD: 0000-0001-7911-0752

28

29 **ABSTRACT**

30 **Background:** Saliva RT-PCR is an attractive alternative for the detection of SARS-  
31 CoV-2 in adults with much less known in children.

32 **Methods:** Children and adolescents with symptoms suggestive of COVID-19 were  
33 prospectively enrolled in a comparative clinical trial of saliva and nasopharyngeal  
34 (NP) RT-PCR between November and December 2020. Detection rates and  
35 sensitivities of saliva and NP RT-PCR were compared. Participants with discordant  
36 NP and saliva RT-PCR results including viral load (VL) were also analyzed.

37 **Result:** Out of 405 patients enrolled, 397 patients had two tests performed. Mean  
38 age was 12.7 years (range 1.2-17.9). Detection rates were 22.9% (95%CI 18.8-  
39 27.1%) by saliva RT-PCR, 25.4% (21.2-29.7%) by NP RT-PCR, and 26.7% (22.4-  
40 31.1%) by any test. The sensitivity of saliva was 85.2% (78.2-92.1%) when using NP  
41 as the gold standard; in contrast, when saliva was considered the gold standard, the  
42 sensitivity of NP was 94.5% (89.8-99.2%). For a NP RT-PCR VL threshold of  $\geq 10^3$   
43 and  $\geq 10^4$  copies/ml, sensitivity of saliva increases to 88.7% and 95.2% respectively.  
44 Sensitivity of saliva and NP swabs was respectively 89.5% and 95.3% in patient with  
45 symptoms less than 4 days ( $p=0.249$ ) and 70.0% and 95.0% in those with symptoms  
46  $\geq 4$  to 7 days ( $p=0.096$ ). The 15 patients who had an isolated positive NP RT-PCR  
47 were significantly younger ( $p=0.034$ ), had a lower NP VL (median  $5.6 \times 10^3$  vs  $3.9 \times 10^7$ ,  
48  $p < 0.001$ ), and were not able to drool saliva at the end of the sampling ( $p=0.002$ ). VLs  
49 were significantly lower with saliva PCR than with NP RT-PCR (median 8.7 cp/ml  
50  $\times 10^4$ ; IQR  $1.2 \times 10^4$ - $5.2 \times 10^5$ ; vs median  $4.0 \times 10^7$  cp/ml; IQR  $8.6 \times 10^5$ - $1. \times 10^8$ ;  $p < 0.001$ ).

51

52 **Conclusion:** Saliva PCR shows diagnostic performances close to NP RT-PCR for  
53 SARS-CoV2 detection in most symptomatic outpatient children and adolescents.

## 54 **Introduction**

55 Diagnosis for SARS-CoV-2 is pivotal in the management of Coronavirus disease  
56 2019 (COVID-19). Accurate and prompt testing of symptomatic children is the  
57 foundation for public health decision-making and implementation of appropriate  
58 measures including isolation and quarantine <sup>1</sup>.

59 The Infectious Diseases Society of America (IDSA) guidelines recommend testing for  
60 SARS-CoV-2 by RT-PCR on specimens including NP swabs, mid-turbinate swabs,  
61 nasal swabs or saliva swabs, NP swabs being referenced as the gold standard  
62 specimen <sup>2,3</sup>. However, NP swab collection is an unpleasant procedure that can  
63 sometimes result in mucous membrane erosions with nasal bleeding, especially in  
64 children <sup>4</sup>. In addition, NP swabs require trained staff for collection and can be  
65 hampered by supply shortages in swabs and transport media. Saliva has already  
66 been reported as an attractive alternative for the detection of SARS-CoV-2 and other  
67 respiratory viruses such as Influenza in adult patients <sup>3,5</sup>. A recent meta-analysis,  
68 reported a sensitivity of 83.2% (95%CI 74.7-91.4%) and 84.8% (95%CI 76.8-92.4%)  
69 for saliva and NP samples respectively <sup>6</sup>.

70 The use of NP swabs for SARS-CoV-2 detection limits the widespread screening of  
71 children <sup>7</sup>. Given the overlap of symptoms caused by SARS-CoV-2 and other  
72 respiratory viruses, children qualify for SARS-CoV-2 testing very often. As a result, a  
73 simple specimen collection such as saliva that avoids unnecessary discomfort is  
74 particularly attractive in children. Saliva collection has also a practical advantage

75 since it can be performed quickly by the patient itself or by the caregiver. Altogether,  
76 the use of saliva specimens would speed up the collection process <sup>7</sup>.

77 Pediatric evidence for the use of saliva specimens by RT- PCR for detection of  
78 SARS-CoV-2 remains weak with sensitivities varying from 52.9% up to 85.0%  
79 reported from small sample sizes when using NP as the gold standard. <sup>8,9</sup> This  
80 ancillary study of the adult RADICO project <sup>10</sup> aims to prospectively compare the  
81 paired saliva and NP samples collected from symptomatic children consulting in  
82 outpatient settings for the detection of SARS-CoV-2. The secondary objectives were  
83 to compare discordant NP and saliva RT-PCR findings as well as their VL.

84

## 85 **Methods**

### 86 ***Study design, setting and populations***

87 This study is an observational prospective multicenter comparative study. Children  
88 aged 1 month to 18 years were recruited from two different outpatient clinics in  
89 Lausanne (Montétan screening site, Department Mother-Woman-Child; Lausanne  
90 University Hospital and Vidy-Med Pediatric Emergency Center) when presenting with  
91 symptoms compatible with COVID-19 according to national guidelines([check.bag-](https://www.check.bag-coronavirus.ch/screening)  
92 [coronavirus.ch/screening](https://www.check.bag-coronavirus.ch/screening))<sup>11</sup>. Children aged 12 and over who reported at least one of  
93 the following symptom including fever, respiratory symptoms such as cough, throat  
94 pain, dyspnea or thoracic pain, anosmia, dysgeusia or a least one minor symptom  
95 and close contact with a documented COVID-19 case were invited to be tested for  
96 SARS-CoV-2 ([check.bag-coronavirus.ch/screening](https://www.check.bag-coronavirus.ch/screening)). Testing criteria were more  
97 restrictive for children under 12 years of age<sup>11</sup> ([www.coronabambini.ch](https://www.coronabambini.ch)). For children

98 without known contact with a SARS-CoV-2 positive case, testing criteria included a  
99 new onset of fever (>38.5 C), a severe cough associated with a bad general  
100 condition or the same symptoms persisting over 3 days in those with a good general  
101 condition. In addition, children with a good clinical condition presenting with a new  
102 onset of fever or a severe cough associated with other COVID-19 compatible  
103 symptoms such as gastrointestinal symptoms, myalgia, headaches, or  
104 anosmia/ageusia were also tested for SARS-CoV-2. Children with any symptom  
105 exposed to a confirmed SARS-CoV-2 positive index case were also tested for SARS-  
106 CoV-2.

107 Informed consent from the legal guardians or adolescents  $\geq 14$  years were mandatory  
108 for inclusion. Exclusion criteria included hospitalized children, those requiring  
109 anticoagulation, and children with a documented past SARS-CoV-2 infection.

110 This study was approved by the ethics committee of Canton de Vaud (CER-VD 2020-  
111 02269) and conducted in accordance with the principles of the Declaration of  
112 Helsinki, the standards of Good Clinical Practice, and Swiss regulatory requirements.

### 113 ***Study procedures***

114 Saliva specimens for RT-PCR analyses were collected either by a healthcare  
115 professional, the patient itself, or its caregiver under supervision, following a  
116 standard procedure that included swabbing of the oral mucosa and drooling saliva in  
117 a tube when possible <sup>10,12</sup>. The healthcare professional collected concomitantly one  
118 NP swab for RT-PCR. Saliva and NP samples collected in viral transport media  
119 (VTM) were sent the same day or the next morning to the molecular diagnostics  
120 laboratory for RT-PCR analyses.

121 General information including age, gender, type and duration of symptoms, and  
122 information on the quality of the saliva sample were collected by the healthcare  
123 worker on an electronic case report form (REDCap®). The results of both NP swabs  
124 and saliva samples were next reported in REDCap® by the study investigators.

### 125 ***SARS-CoV-2 RT-PCR, cycle thresholds (CT) and viral load (VL) quantification***

126 SARS-CoV-2 RT-PCR were performed using an in-house RT-PCR on the automated  
127 molecular diagnostic platform targeting the E gene<sup>13-15</sup> or using the SARS-CoV-2  
128 test of the Cobas® 6800 instrument (Roche, Basel, Switzerland)<sup>16</sup>. The cycle  
129 threshold (cycle when the RT-PCR was positive, i.e above the threshold of  
130 fluorescence) was provided automatically by the instruments by using the default  
131 parameters. Viral load was then obtained by converting (CT) of the RT-PCR  
132 instruments, using the formula  $\log VL = -0.27Ct + 13.04$ , as previously reported<sup>17,18</sup>.

### 133 ***Outcomes***

134 The primary outcome was the proportion of SARS-CoV-2 positive children detected  
135 from saliva samples and NP swabs by RT-PCR assays. The secondary outcome was  
136 the viral loads of SARS-CoV-2 measured by RT-PCR assays on saliva and NP  
137 samples

### 138 ***Statistical analysis***

139 The estimated sample size was 50 positives among 500 cases tested to have a  
140 precision of +/-2% on the detection rate if the latter was 20%. All patients having a  
141 result available for the 2 tests were included in the study analysis population.  
142 Standard descriptive and comparative statistics were performed. The Chi-square test

143 was used to compare categorical variables between groups, as appropriate for  
144 comparison between proportions. A Student t-test was used to compare continuous  
145 variables when the normality of the distribution was visually accepted. For skewed  
146 data, we derived medians and used the Mann–Whitney method for comparison. We  
147 estimated the detection rate and sensitivity of each test with 95% CIs. The sensitivity  
148 of saliva and NP samples was first calculated by using each other as the gold  
149 standard. Next, a composite gold standard combining any positive RT-PCR result  
150 reported from saliva and/or NP swabs was used to determine the sensitivity of both  
151 samples. Stratified subgroup analyses for different age groups were conducted.  
152 Participants were divided into 3 age groups: 0-6, ≥6-12, and ≥12 years of age and 3  
153 symptom duration groups: 0-3, ≥4-7, and >7 days . Post-hoc analyses using the  
154 Bonferroni correction were performed between age groups (age group effect:  $p$   
155  $<0.017$  ( $0.05/3$ )) that presented statistically significant different detection rates and  
156 sensitivities. Univariable linear regression was used to compare the clinical correlates  
157 (duration of symptoms and age of patients) to NP or saliva sample viral loads.  
158 Statistical analyses were computed using R software, v 3.6.1, and the 2019 R Studio  
159 interface (R Studio Team, Boston, MA).

## 160 **Results**

### 161 *Patient characteristics*

162 Eight hundred and seventy-eight children and adolescents were screened between  
163 November 4<sup>th</sup> and December 12<sup>th</sup>, 2020 for SARS-CoV-2. Among them, 405 children  
164 were included in this study, of whom the 397 who had both NP and saliva samples  
165 collected were included in the analyses. The mean age was 12.7 years (Standard  
166 Deviation (SD) 3.8, range 1.2 to 17.9). One hundred and ninety-two patients (48.3%)

167 were females. The characteristics of the patient population stratified by SARS-CoV-2  
168 positive and negative results are summarized in Table 1.

169 The mean time between the onset of symptoms and the collection of the NP and  
170 saliva samples was 2.4 days (SD 1.8, range 0 to 10) with no significant differences  
171 reported in the duration of symptoms between children under 12 years of age and  
172 those aged 12 and over ( $p=0.697$ ). A vast majority of children of  $\geq 12$  years of age  
173 presented at least one major symptom (89.9%), mostly sore throat (68.6%), cough  
174 (49.5%), fever (25.6%), dysgeusia (13.4%) and anosmia (10.5%). The remaining  
175 10.1% (28/278) suffered from at least one minor symptom while having close contact  
176 with a documented COVID-19 case. From children  $< 12$  years of age, 81.5 % (97/117)  
177 presented with fever (47.9%) and/or a severe cough (52.1%) associated at least with  
178 a bad general condition, other manifestations suggestive of COVID-19 or symptoms  
179 lasting more than 3 days. The remaining 18.5% (22/117) suffered from at least one  
180 symptom suggestive of COVID-19 and had close contact with a documented COVID-  
181 19 case.

182

### 183 *Detection rates of NP RT-PCR and saliva RT- PCR*

184 Of the 397 participants included in the analyses, 91 (22.9%; 18.8-27.1%) tested  
185 positive by saliva samples, 101 (25.4%; 21.2-29.7%) by NP swabs, and 106 (26.7%;  
186 22.4-31.1%) by any of the 2 samples. Detection rates were equivalent for both NP  
187 and saliva specimens (-8.7 to 3.7%,  $p=0.457$ ). Respectively 15 and 5 children were  
188 detected positive only on NP swabs or saliva specimens. The detection rates by age  
189 categories (0-6,  $\geq 6-12$ , and  $\geq 12$  years of age) were significantly different for saliva  
190 samples ( $p=0.007$ ) but not for NP swabs ( $p=0.070$ ). Yet, this remained only



191 statistically different in post-hoc analyses between the age groups of 0-6 years and  
192  $\geq 6$ -12 years with a higher detection rate among children of  $\geq 6$ -12 years of age (3.2%  
193 vs 30.7 %,  $p=0.004$ ) (Figure 1)

194 *Diagnostic test performance (sensitivity, specificity) of NP RT-PCR and saliva RT-*  
195 *PCR*

196 Using NP as the gold standard, the sensitivity of saliva was 85.2% (95%CI 78.2-  
197 92.1%); in contrast, when saliva was considered the gold standard, the sensitivity of  
198 NP was 94.5% (95%CI 89.8-99.2%) ( $p=0.058$ ). The sensitivity of saliva RT-PCR was  
199 dependent on NP VLs and was maximal with a viral load of  $10^6$  cp/ml. (Table 2 and  
200 Figure 2). When using the composite reference as the gold standard, the respective  
201 sensitivity of saliva and NP swabs was 85.9% (95%CI 79.2-92.5%) and 95.3%  
202 (95%CI 91.3-99.3%) ( $p=0.034$ ). When stratified by age groups, the respective  
203 sensitivity of saliva and NP swabs was 89.9% and 97.1% in children aged  $\geq 12$  years  
204 and 84.4% and 90.6% in children  $\geq 6$  to 12 years of age. In children under 6 years of  
205 age, 4 patients were detected positive from NP swabs, whereas only one child was  
206 documented positive from saliva. As a result, the reported sensitivity was only 25%  
207 for saliva PCR and 100% for NP swabs in this subgroup. The reported sensitivity was  
208 significantly different between age groups for saliva samples ( $p=0.0001$ ) but not for  
209 NP swabs ( $p=0.320$ ). Yet, in post-hoc analyses, sensitivity for saliva remained  
210 statistically different only between the 0-6 year subgroup compared to the one  
211 including children of 12 years of age and onwards (25% vs 89,9%,  $p=0.003$ ). When  
212 stratified by the duration of symptoms, the respective sensitivity of saliva and NP  
213 swabs was 89.5% and 95.3% in patient with symptom duration  $< 4$  days (95%CI -  
214 14.8 to 3.2%,  $p=0.249$ ) and 70.0% and 95.0% in those with symptom duration

215 (95%CI -52.2 to 2.2%,  $p=0.096$ )  $\geq$  4 to 7 days. Only 3 patients had symptoms above  
216 7 days and all were tested negative from both samples.

### 217 *Viral loads*

218 Figures 3A and 3B display the distribution of VLs and CT by analyzed specimen. VLs  
219 documented from saliva were significantly lower compared to those reported from  
220 paired NP swabs (median  $8.7 \text{ cp/ml} \times 10^4$ ; IQR  $1.2 \times 10^4$ - $5.2 \times 10^5$ ; vs median  
221  $4.0 \times 10^7 \text{ cp/ml}$ ; IQR  $8.6 \times 10^5$ - $1. \times 10^8$ ;  $p < 0.001$ , 95CI:  $-4.5 \times 10^2$  to  $-7.7 \times 10^1$ ). VLs  
222 measured from saliva increased significantly with age but not with the duration of  
223 symptoms (Figure 4A/B). VLs measured from NP were not affected by age. (Figure  
224 4A).

### 225 *Comparison of discordant NP and saliva RT-PCR results*

226 Table 3 displays the characteristics of the 15 children with NP swabs only positive  
227 compared to the 86 documented positive from both NP swabs and saliva samples.  
228 Children with isolated SARS-CoV-2 positive NP swabs were significantly younger  
229 ( $p=0.034$ ) and with significantly lower NP VLs (median  $5.6 \times 10^3$  vs  $3.9 \times 10^7$ ,  $p < 0.001$ )  
230 compared to those with both saliva and NP positive specimens. In addition, they  
231 were not able to drool at the end of saliva collection ( $p=0.002$ ). Variables such as the  
232 duration of symptoms or the person who performed the procedure did not affect the  
233 above findings. The 5 patients who had isolated positive saliva samples were all  
234 males, had a median age of 11.1 y (10.3-14.6), and presented with median VLs of  
235  $4.0 \times 10^3 \text{ cp/ml}$  ( $1.1 \times 10^3$ - $8.8 \times 10^3$ ).

236

## 237 **Discussion**

238 The overall detection rate for SARS-CoV-2 between saliva and NP specimens by RT-  
239 PCR was comparable. However, a significantly lower sensitivity was reported from  
240 saliva specimens compared to NP swabs when compared to any positive test. Yet,  
241 the sensitivity of saliva increased with VLs and was equivalent to NP swabs when  
242 using a VL threshold of  $\geq 10^4$  copies/ml. The procedure of saliva collection and  
243 younger age affected the detection of SARS-CoV-2 in saliva. In contrast, the duration  
244 of symptoms over 7 days of onset did not significantly affect the sensitivity of SARS-  
245 CoV-2 detection in saliva.

246 With more than twice as many children included <sup>8</sup>, this study is by far, the largest  
247 cohort reporting on the performance of saliva specimens in children. As supported by  
248 another study including children <sup>8</sup> and other studies conducted in adults <sup>10,19</sup>, a  
249 detection rates slightly lower of SARS-COV-2 were reported from saliva as compared  
250 to NP specimens, yet still supporting the use of saliva as an alternative to NP swabs  
251 in children. Moreover, our findings are in line with the RADICO study conducted in  
252 symptomatic adults, that used the same saliva collection approach <sup>10</sup>. In contrast,  
253 other studies indicated a poor concordance between NP and saliva specimens <sup>9,20,21</sup>,  
254 likely as a result of using different sampling procedures that did not necessarily  
255 include saliva drooling. In addition, the inclusion of adults and children with a variable  
256 duration of symptoms upon testing and asymptomatic patients possibly limited their  
257 conclusions.

258 The sensitivity of RT-PCR assays reported from saliva was lower compared to NP  
259 swabs and the gold standard test, albeit only reaching statistical difference when  
260 compared to any positive test. This difference in sensitivity is likely explained by a 2

261 log lower VL detection in saliva compared to NP samples as evidenced elsewhere  
262 <sup>9,10,22</sup>. Furthermore, SARS-CoV-2 detection in saliva is dependent on viral loads and  
263 reaches an equivalent sensitivity to NP swabs for NP VL thresholds of  $10^4$  copies/ml.  
264 Recent studies <sup>23-25</sup> suggest that no cultivable viable virus is detected from patients  
265 with VLs under the threshold of  $10^4$  copies/ml. Altogether ours and others findings  
266 suggest <sup>8</sup> that children detected SARS-CoV-2 negative from saliva samples  
267 presented VLs under the threshold of  $10^4$  copies/ml from their NP and were thereby  
268 potentially less contagious. The use of saliva as an alternative to NP for SARS-CoV-  
269 2 detection in children would thus limit quarantine measures to most contagious  
270 children <sup>26</sup>.

271 Younger age significantly affected the detection rates and the sensitivity of SARS-  
272 CoV-2 in saliva as supported by a significantly reduced sensitivity of saliva  
273 documented among children under 6 years of age compared to those of 12 years of  
274 age and onwards. Furthermore, children who only detected positive from their NP  
275 swabs were significantly younger compared to those documented SARS-CoV-2  
276 positive from both specimens. The significant linear association documented  
277 between age and VLs supported that lower VLs documented among younger  
278 children likely affected the sensitivity of saliva for SARS-CoV-2 detection. Yet,  
279 children under 6 years of age only represented 8% of our cohort, thereby limiting our  
280 conclusions. In addition, the incomplete procedure for saliva collection observed  
281 among younger children might have impacted the sensitivity, as most of the 15  
282 children only documented SARS-CoV-2 positive from their NP swabs were not able  
283 to drool. Yet, data from the RADICO study reported no impact of drooling on the  
284 sensitivity of saliva nor the VL count <sup>10</sup>. Whether drooling affects the sensitivity of  
285 saliva remains an open debate and should be investigated in future pediatric studies.

286 Furthermore, drooling into the tube also raises biosafety concerns. The edge of the  
287 tube can be contaminated thereby questioning the use of precautionary measures.  
288 Duration of symptoms over 7 days of onset did not significantly affect the sensitivity  
289 of SARS-CoV-2 detection in saliva as already supported in other adult <sup>19</sup> and  
290 paediatrics <sup>9</sup> studies.

291 Strengths of the current study include the largest pediatric sample size collected so  
292 far in addition to the detailed prospectively collected information. Limitations are  
293 predominantly related to the inclusion of outpatients and not hospitalized nor  
294 asymptomatic children, which might affect the generalizability of our findings.  
295 Furthermore, young children were under-represented and only a few of them were  
296 detected SARS-CoV2 positive, thus limiting extrapolation to this age-group. In  
297 addition, our study was conducted during a high prevalence of SARS-CoV-2 (up to  
298 30%), thereby affecting our positive predicted values. Finally, our study was  
299 conducted before the introduction of 501Y mutants in Switzerland, which currently  
300 represent 8 to 15% of the analyzed samples. As such, we were not able to compare  
301 the performance of mutant typing in saliva vs NP. Yet, recent evidence supports that  
302 the lower VLs detected from saliva limit mutant typing analyses <sup>27</sup>.

### 303 **Conclusion:**

304 In conclusion, saliva is a reliable alternative for SARS-CoV-2 detection among  
305 symptomatic children. Saliva collection being a non-invasive easy procedure will  
306 facilitate large-scale screening in children and thus provide more evidence on the  
307 impact of SARS-CoV-2 in children.

308

309 **Funding**

310 The saliva PCR were paid for by the cantonal health authorities.

311 **Acknowledgments:**

312 We thank Marion de Vallière and Maria Daniela Garrido for help in patient  
313 recruitment, the patients for participation in this study, and the health authorities of  
314 the Canton de Vaud for their support. We would like to thank the Vidy-Med team and  
315 the Montétan screening site teams for the recruitment of participants. We thank all  
316 the team of the Laboratory of Molecular Diagnostics of the Institute of Microbiology  
317 and Anne Tabard-Fougère for her help in the statistical analyses and figure  
318 elaboration.

319 **Conflict of interest**

320 None

321

322 **Bibliography:**

- 323 1. Marcel S, Christian AL, Richard N, et al. COVID-19 epidemic in Switzerland: On the  
324 importance of testing, contact tracing and isolation. *Swiss Med Wkly*. 2020;150(11-  
325 12):4-6. doi:10.4414/smw.2020.20225
- 326 2. Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities  
327 in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). *Clin Chem Lab*  
328 *Med*. 2020;58(7):1070-1076. doi:10.1515/cclm-2020-0285
- 329 3. Hanson KE, Caliendo AM, Arias CA, et al. *The Infectious Diseases Society of America*  
330 *Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing Authors.*;  
331 2020:1-70. [www.idsociety.org/COVID19guidelines/dx](http://www.idsociety.org/COVID19guidelines/dx).
- 332 4. Li L, Shim T, Zapanta PE. Optimization of COVID-19 testing accuracy with nasal  
333 anatomy education. *Am J Otolaryngol Neck Med Surg*. 2020;42(1):1-4.
- 334 5. Kim YG, Yun SG, Kim MY, et al. Comparison between saliva and nasopharyngeal swab  
335 specimens for detection of respiratory viruses by multiplex reverse transcription-PCR.  
336 *J Clin Microbiol*. 2017;55(1):226-233. doi:10.1128/JCM.01704-16

- 337 6. Butler-Laporte G, Lawandi A, Schiller I, et al. Comparison of Saliva and Nasopharyngeal  
338 Swab Nucleic Acid Amplification Testing for Detection of SARS-CoV-2. *JAMA Intern*  
339 *Med.* 2021;1-8. doi:10.1001/jamainternmed.2020.8876
- 340 7. Ruggiero A, Sanguinetti M, Gatto A, Attinà G, Chiaretti A. Diagnosis of COVID-19  
341 infection in children: Less nasopharyngeal swabs, more saliva. *Acta Paediatr Int J*  
342 *Paediatr.* 2020;109(9):1913-1914. doi:10.1111/apa.15397
- 343 8. Yee R, Truong T, Pannaraj PS, et al. Saliva is a promising alternative specimen for the  
344 detection of SARS-CoV-2 in children and adults. *J Clin Microbiol.* 2020;(November).  
345 doi:10.1128/JCM.02686-20
- 346 9. Cousins JN, Teo TB, Tan ZY, Wong KF, Chee MWL, Chee MWL. Saliva is not a useful  
347 diagnostic specimen in children with Coronavirus Disease 2019. 2020.
- 348 10. Jean-Marc S, Miauton A, Petrovic D, et al. Antigen rapid tests , nasopharyngeal PCR  
349 and saliva PCR to detect SARS-CoV-2: a prospective comparative clinical trial.  
350 *medRxiv.* 2020. doi:doi.org/10.1101/2020.11.23.20237057
- 351 11. BAG, SSP, Association professionnelle de la pédiatrie Ambulatoire. Recommandation  
352 sur la procédure à suivre pour les enfants symptomatiques de moins de 12 ans et les  
353 autres personnes fréquentant les écoles et les structures d'accueil parascolaires et  
354 extrafamiliales et indications de test chez les enfants de moins de 12.  
355 [https://www.bag.admin.ch/dam/bag/fr/dokumente/mt/k-und-i/aktuelle-ausbrueche-](https://www.bag.admin.ch/dam/bag/fr/dokumente/mt/k-und-i/aktuelle-ausbrueche-pandemien/2019-nCoV/testkriterien-kinder.pdf.download.pdf/Criteres_de_test_pour_les_enfants.pdf)  
356 [pandemien/2019-nCoV/testkriterien-](https://www.bag.admin.ch/dam/bag/fr/dokumente/mt/k-und-i/aktuelle-ausbrueche-pandemien/2019-nCoV/testkriterien-kinder.pdf.download.pdf/Criteres_de_test_pour_les_enfants.pdf)  
357 [kinder.pdf.download.pdf/Criteres\\_de\\_test\\_pour\\_les\\_enfants.pdf](https://www.bag.admin.ch/dam/bag/fr/dokumente/mt/k-und-i/aktuelle-ausbrueche-pandemien/2019-nCoV/testkriterien-kinder.pdf.download.pdf/Criteres_de_test_pour_les_enfants.pdf). Published 2020.
- 358 12. GIC Delaware. Delaware COVID-19 Saliva Test Instructions.  
359 [https://www.youtube.com/watch?v=Eb3vSTc150U&feature=emb\\_logo](https://www.youtube.com/watch?v=Eb3vSTc150U&feature=emb_logo). Published  
360 2020.
- 361 13. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 -nCoV by RT-PCR. *Euro*  
362 *Surveill.* 2020;25(3):1-8.
- 363 14. Pillonel T, Scherz V, Jatton K, Greub G, Bertelli C. Letter to the editor: SARS-CoV-2  
364 detection by real-time RT-PCR. *Eurosurveillance.* 2020;25(21):1-2. doi:10.2807/1560-  
365 7917.ES.2020.25.21.2000880
- 366 15. Greub G, Sahli R, Brouillet R, Jatton K. Ten years of R&D and full automation in  
367 molecular diagnosis. *Future Microbiol.* 2016;11(3):403-425. doi:10.2217/fmb.15.152
- 368 16. Roche Molecular Diagnostics. Cobas® 6800/8800 Systems: Specifications.  
369 [https://diagnostics.roche.com/content/dam/diagnostics/Blueprint/en/pdf/rmd/RMD](https://diagnostics.roche.com/content/dam/diagnostics/Blueprint/en/pdf/rmd/RMD_cobas_6800_8000_07353898001_4_Systems_SpecTech_SS-1.pdf)  
370 [\\_cobas\\_6800\\_8000\\_07353898001\\_4\\_Systems\\_SpecTech\\_SS-1.pdf](https://diagnostics.roche.com/content/dam/diagnostics/Blueprint/en/pdf/rmd/RMD_cobas_6800_8000_07353898001_4_Systems_SpecTech_SS-1.pdf). Published 2015.
- 371 17. Jacot D, Greub G, Jatton K, Opota O. Viral load of SARS-CoV-2 across patients and  
372 compared to other respiratory viruses. *Microbes Infect.* 2020;22(10):617-621.  
373 doi:10.1016/j.micinf.2020.08.004
- 374 18. Opota O, Brouillet R, Greub G, Jatton K. Comparison of SARS-CoV-2 RT-PCR on a high-  
375 throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the  
376 diagnostic of COVID-19 on various clinical samples. *Onyia. Pathog Dis.* 2020.  
377 doi:10.1093/femspd/ftaa061
- 378 19. Simonov M, Datta R, Handoko R, et al. Saliva or Nasopharyngeal Swab Specimens for  
379 Detection of SARS-CoV-2. *N Engl J Med.* 2020;383:1283.

- 380 20. Silva RCM da, Marinho LCN, Silva DN de A, et al. Saliva as a possible tool for the SARS-  
381 CoV-2 detection: A review. *Travel Med Infect Dis.* 2020;38:1-12.
- 382 21. Czumbel LM, Kiss S, Farkas N, et al. Saliva as a Candidate for COVID-19 Diagnostic  
383 Testing: A Meta-Analysis. *Front Med.* 2020;7(August):1-10.  
384 doi:10.3389/fmed.2020.00465
- 385 22. Jamal AJ, Mozafarihashjin M, Coomes E, et al. Sensitivity of Nasopharyngeal Swabs  
386 and Saliva for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2. *Clin*  
387 *Infect Dis.* 2020;27(Xx Xxxx):9-11. doi:10.1093/cid/ciaa848
- 388 23. L'Huillier AG, Torriani G, Pigny F, Kaiser L, Eckerle I. Culture-Competent SARS-CoV-2 in  
389 Nasopharynx of Symptomatic Neonates, Children, and Adolescents. *Emerg Infect Dis.*  
390 2020;26(10):2494-2497. doi:10.3201/eid2610.202403
- 391 24. Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation  
392 with RT-PCR cycle threshold values in cases of COVID-19, England, January to May  
393 2020. *Eurosurveillance.* 2020;25(32):1-5. doi:10.2807/1560-  
394 7917.ES.2020.25.32.2001483
- 395 25. Jaafar R, Aherfi S, Wurtz N, et al. Correlation between 3790 qPCR positives samples  
396 and positive cell cultures including 1941 SARS-CoV-2 isolates. *Clin Chem Lab Med.*  
397 2020:1-8. doi:10.1093/cid/ciaa1491
- 398 26. Turner F, Vandenberg A, Slepnev VI, Car S, Starritt RE, Seger M V. Post-Disease  
399 Divergence in SARS-CoV-2 RNA Detection between Nasopharyngeal, Anterior Nares  
400 and Saliva/Oral Fluid Specimens - Significant Implications for Policy & Public Health.  
401 *medRxiv Prepr.* 2021:1-19.
- 402 27. Leung K, Shum MH, Leung GM, Lam TT, Wu JT, Ty T. Early empirical assessment of the  
403 N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November  
404 2020. *Eurosurveillance.* 2020;26(1):2020.12.20.20248581. doi:10.2807/1560-  
405 7917.ES.2020.26.1.2002106

406

#### 407 **Figure captions**

#### 408 **Figure 1: Detection rate for NP and saliva PCR by age categories**

409 NP= Nasopharyngeal

#### 410 **Figure 2: Sensitivity of saliva PCR in relation to NP viral loads**

411 NP= Nasopharyngeal

#### 412 **Figure 3: Distribution of viral load and CT according to the type of sample**

413 NP= Nasopharyngeal


#### 414 **Figure 4: Relation of viral loads to symptom duration and age**

415









**A) Distribution of Positive PCR Saliva by age**



**B) Distribution of Positive PCR NP by age**










Table 1. Characteristics stratified by SARS-CoV-2 positive or negative results

Legend: NP: Nasopharyngeal swab, SD= Standard Deviation

| Characteristics                      | All, n=397  | SARS-CoV-2 positive, n=106 | SARS-CoV-2 negative, n=291 | P value | 95% Confidence Interval |
|--------------------------------------|-------------|----------------------------|----------------------------|---------|-------------------------|
| <b>Demographics</b>                  |             |                            |                            |         |                         |
| Female, n (%)                        | 192 (48.3%) | 47 (44.3%)                 | 145 (49.8%)                | 0.393   | -17.2 to 6.2%           |
| Age, mean years (SD)                 | 12.7 (3.8)  | 12.7 (3.7)                 | 12.6 (3.8)                 | 0.904   | -0.8 to 0.9             |
| <12 years, n (%)                     | 119 (30%)   | 36 (34.0%)                 | 83 (28.5%)                 | 0.356   | -5.6 to 16.5%           |
| Duration of symptoms, mean days (SD) | 2.4 (1.8)   | 2.3 (1.6)                  | 2.5 (1.8)                  | 0.428   | -0.5 to 0.2             |
| <b>Saliva sampling:</b>              |             |                            |                            |         |                         |
| Able to drool saliva, n (%)          | 368 (92.7%) | 100 (94.3%)                | 268 (92.1%)                | 0.588   | -3.8 to 83%             |
| <u>Tested by the:</u>                |             |                            |                            |         |                         |
| Patient, n (%)                       | 202 (50.9%) | 59 (55.7%)                 | 143 (49.1%)                | 0.300   | -5.2 to 18.2%           |
| Adult (Parent or caregiver), n (%)   | 187 (47.1%) | 46(43.4%)                  | 141 (48.5%)                | 0.436   | -16.7 to 6.6%           |
| Patient + adult n (%)                | 8 (4.5%)    | 1 (0.9%)                   | 7 (2.4%)                   | 0.608   | -4.7 to 1.7%            |

**Table 2.** Sensitivity of saliva RT-PCR compared to NP RT-PCR stratified by viral load thresholds.

Legend: NP: Nasopharyngeal swab, VL= viral load

|                               |                    | <b>Sensitivity</b> |                 |                 |                 |
|-------------------------------|--------------------|--------------------|-----------------|-----------------|-----------------|
| <b>VL ≥</b>                   | <b>VL &lt;1e+3</b> | <b>VL ≥1e+3</b>    | <b>VL ≥1e+4</b> | <b>VL ≥1e+5</b> | <b>VL ≥1e+6</b> |
| <b>Saliva PCR Sensitivity</b> | 85.1%              | 88.7%              | 95.2%           | 97.3%           | 98.4%           |

**Table 3.** Characteristics stratified by the concordance of positive NP and saliva RT-PCR findings  
Legend: NP: Nasopharyngeal swabs, VL= viral loads, IQR= interquartile range

| Characteristics                        | Negative saliva PCR,<br>NP PCR + n=15                              | NP and<br>saliva<br>PCR +,<br>n=86                                 | P value          | 95%<br>Confidence<br>interval                |
|--|--|--|------------------|--|
| Age, median (IQR)                      | 11.2 (7.3-14.0)  | 14.1 (11.8-15.4)   | <b>0.034</b>     | -4.7 to -0.2                                 |
| Female, n (%)                          | 9 (60.0%)  | 45 (52.3%)   | 0.788            | -23.2 to 38.5%                               |
| Duration of symptoms, median,<br>(IQR) | 3 (1.5-4.5)  | 2 (1-3)  | 0.094            | 0 to 2                                       |
| NP viral load, median (IQR)            | 5.6x10 <sup>3</sup><br>(1.5x10 <sup>3</sup> -1.0x10 <sup>4</sup> ) | 3.9x10 <sup>7</sup><br>(8.6x10 <sup>5</sup> -1.0x10 <sup>8</sup> ) | <b>&lt;0.001</b> | -1.5x10 <sup>4</sup> to -4.6x10 <sup>2</sup> |
| <b><u>Tested by the:</u></b>           |  |  |                  |  |
| Participant, n (%)                     | 7 (46.7)   | 50(58.1%)  | 0.586            | -42.7 to 19.8%                               |
| Adult (Parent or caregiver), n (%)     | 8 (53.3)   | 35 (40.7 %)  | 0.529            | -18.6 to 43.8%                               |
| Patient + Adult, n (%)                 | 0 (0.0 %)  | 1(1.1%)  | 1.000            | -4.6 to 2.3%                                 |
| Able to drool saliva, n (%)            | 11(73.3%)  | 84(97.7%)  | <b>0.002</b>     | -50.9 to 2.2%                                |

IQR= interquartile range